L. Douglas Case, PhD


L. Douglas Case, PhDL. Douglas Case, PhD
Department of Biostatistical Sciences
Section on Biostatistics
Wake Forest School of Medicine
Medical Center Blvd.
Winston-Salem, North Carolina 27157
Tel: 336-716-1048
Fax: 336-716-5425
Email: dcase@wakehealth.edu



UNC-Chapel Hill, BS, Mathematics
UNC-Chapel Hill, MSPH, Biostatistics
UNC-Chapel Hill, PhD, Biostatistics 


Dr. Case obtained a PhD in Biostatistics from the University of North Carolina at Chapel Hill in 1987. He is currently a Professor of Biostatistics in the Department of Public Health Sciences at the Wake Forest University School of Medicine. He served as Director of the Biostatistics Core of the Comprehensive Cancer Center at Wake Forest University from 1991 to 2001, working actively with clinical, cancer control, and basic scientists in designing new studies and analyzing the resulting data. He served as a co-investigator for the FoCaS project, a study to develop, implement and evaluate a program designed to increase utilization of cervical and breast cancer screening among low income, low education, minority women, and he was the PI of the Biostatistics Core for the Breast Cancer Center of Excellence, a DOD funded longitudinal study examining menstrual bleeding and health related quality of life following the diagnosis and treatment of breast cancer, and the PI of the Statistical Center for the Ischemic Stroke Genetics Study, a case-control study assessing the associations between genetic factors and the risk of stroke. Dr. Case is currently the senior statistician for the Wake Forest University Cancer Research Base, a grant supporting the development of cancer clinical trials for use in the community.

Research Topics:

Clinical Trials
Group Sequential Methods
Sample Size Determination
Analysis of Menstrual Bleeding Calendars
Breast Cancer 


Dr. Case’s primary research interests are related to the design and analysis of clinical trials, particularly the development of new group sequential plans and the application of statistical methodology to cancer research. He is currently working on the development of phase II designs for time to event outcomes and methods for sample size determination, the analysis of survival data, and the analysis of menstrual bleeding data.

Recent Peer-Reviewed Publications:

Sukumvanich P, Case LD, Van Zee K, Singletary SE, Paskett ED, Petrek JA, Naftalis E, Naughton MJ.  Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer 2010 116(13):3102-3111.

Demark-Wahnefried W, Case LD, Blackwell K, Marcom PK, Kraus W, Aziz N, Snyder DC, Giguere JK, Shaw E.  Results of a diet-exercise feasibility trial to prevent adverse body composition change in breast cancer patients on adjuvant chemotherapy.  Clinical Breast Cancer 2008:8;70-79.

Kennedy LD, Case LD, Hurd DD, Cruz JM, Pomper GJ.  A prospective, randomized, double blind controlled trial of acetaminophen and diphenhydramine premedication versus placebo for the prevention of transfusion reactions.  Transfusion 2008:48;2285-2291.

Paskett ED, Naughton MJ, McCoy TP, Case LD, Abbott JM.  The epidemiology of arm and hand swelling in premenopausal breast cancer survivors.  Cancer Epidemiol Biomarkders Prev 2007 Apr;16(4):775-82.

Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, Sukumvanich P.  Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study.  JCO 2006;24:1045-1051.

Michielutte R, Sharp PC, Foley KL, Cunningham LE, Spangler JG, Paskett ED, Case LD.  Intervention to increase screening mammography among women 65 and older.  Health Educ Res 2005;20(2):149-62.

Hu JJ, Hall MC, Grossman L, Hedayati M, McCullough DL, Lohman K, Case LD. Deficient nucleotide excision repair capacity enhances human prostate cancer risk.  Cancer Research 2004;64:1197-1201.

Case LD, Morgan TM.  Design of phase II trials evaluating survival probabilities. BMC Medical Research 2003:3;6.

Kimmick GG, Shelton BJ, Case LD, Cooper MR, Muss HB.  Long-term follow-up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breast.  Breast Cancer Research Treatment 2002;72(3):233-243.

Case LD, Morgan TM.  Duration of accrual and follow-up for two-stage clinical trials.  Lifetime Data Analysis 2001;7(1):21-37.

Last Updated: 01-20-2015
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.